Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 24 2024
0mins
Source: Newsfilter
Business Update: Altamira Therapeutics reported progress in RNA delivery technology, highlighting successful mRNA treatments for cancer and inflammatory diseases, alongside financial results showing a net loss of $4.3 million for the first half of 2024.
Product Expansion: The company is expanding its Bentrio® nasal spray distribution in Asia and Scandinavia while pursuing partnerships for its RNA delivery platforms and inner ear therapeutics, aiming to strengthen its market position.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
